Tracers / [177Lu]Lu-EB-TATE
[177Lu]Lu-EB-TATE
Also written as [Lu-177]Lu-EB-TATE; Lu-177-EB-TATE
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- EB-TATE (Evans blue-conjugated somatostatin analog, SSTR2 agonist)
- Target / mechanism
- SSTR2 agonist targeting somatostatin receptor 2, with albumin-binding Evans blue moiety for prolonged retention PMID 40177560
- Clinical application
- Peptide receptor radionuclide therapy (PRRT) for metastatic/advanced neuroendocrine tumors PMID 40177560
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | EB-TATE | 40177560 2025 Acta Pharm Sin B 177Lu-DOTATATE and 177Lu-EB-TATE were radiolabeled using the same method. |
Need this precursor?We can point you to suppliers for [177Lu]Lu-EB-TATE, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40177560: 'EB-TATE'.